Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biyan Qingdu Granules is a Traditional Chinese Medicine (TCM) product developed and manufactured by Zhongshan Shaxi Chinese Medicine Factory. It is formulated to clear heat, detoxify, and resolve phlegm and masses. The drug is primarily indicated as an adjuvant therapy for patients with nasopharyngeal carcinoma (NPC), particularly to alleviate symptoms and side effects associated with radiotherapy and chemotherapy, such as sore throat, nasal congestion, and headache. It is also used for the treatment of chronic nasopharyngitis. The formulation consists of a complex mixture of herbal ingredients, including *Paris polyphylla*, *Lonicera japonica*, and *Chrysanthemum indicum*, which are traditionally recognized for their anti-inflammatory and potential anti-tumor properties. It is approved for marketing in China and is administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biyan Qingdu Granules.